I understand your point, however I am not sure if your comment about competition in standard of care drugs is correct. As I see it, current standard of care drugs is to enable remission and or stabilise the disease after frontline treatment of surgery, chemotherapy, etc. CF33 has the potential to be a frontline treatment eliminating the need for invasive, painful and ongoing costly treatments that are considered current standard of care. Even if the end result is the same outcome, it is not the same.
Ann: Imugene Presentation to Bell Potter Conference, page-45
-
- There are more pages in this discussion • 115 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.9¢ | $900.1K | 18.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 102 | 15456501 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 1713619 | 8 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |